Industry Briefs

A report on genetically engineered plants predicts that they will begin reaching the marketplace within five years, but when they do, high research and testing costs will allow only the largest companies to compete in the field. Gerald Campbell, a St. Louis biochemist and one of the authors of the report, says the big companies likely to benefit from the technology are Calgene, Du Pont, and Monsanto. Under a contract with Campbell Soup, Calgene is now engaged in field trials of a genetically en

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

A report on genetically engineered plants predicts that they will begin reaching the marketplace within five years, but when they do, high research and testing costs will allow only the largest companies to compete in the field. Gerald Campbell, a St. Louis biochemist and one of the authors of the report, says the big companies likely to benefit from the technology are Calgene, Du Pont, and Monsanto. Under a contract with Campbell Soup, Calgene is now engaged in field trials of a genetically engineered tomato. Through nonexpression of a gene, Calgene researchers have altered the enzyme that causes the softening of ripe tomatoes, thus allowing the plant to spend more time on the vine before harvest. Other promising avenues of research include plants that manufacture their own pesticides and herbicides. Campbell, who wrote the report for Frost & Sullivan Inc., a New York-based market research firm, could not say how ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies